Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Comparing two methods of reducing antiplatelet therapy in heart patients

Official title: Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study - The Switching Antiplatelet-8 (SWAP-8) Study

Run by University of Florida · NCT06821191 · Data updated 2026-11-12

This study is testing two ways to safely lower blood-thinning medication in heart patients after a procedure to see if one method works just as well as the other.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment78 (estimated)
SponsorUniversity of Florida
Academic / other
Locations1 site (Jacksonville, Florida)
StatusRecruiting
StartedMarch 10, 2025
Main results expectedNovember 1, 2026
Study endsJanuary 7, 2027
Registry record updatedMay 12, 2026
Trial IDNCT06821191 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older who have undergone PCI and are currently on DAPT treatment.

Probably not a fit

Patients with a history of stent thrombosis, recent PCI, or those on anticoagulant therapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial compares two strategies for de-escalating dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI) for coronary artery disease. One group will receive a dose reduction of prasugrel to 5 mg, while the other will switch to clopidogrel at a standard dose of 75 mg. The study aims to determine if these two approaches are equally effective in maintaining ischemic protection while reducing the risk of bleeding. It is a non-inferiority trial, meaning it seeks to show that the new strategies are not worse than the current standard.

Why it matters

Potential benefit: If successful, this study could help reduce bleeding risks for patients while still effectively preventing heart-related events.

How similar studies have gone: While there have been various studies on DAPT de-escalation, this specific head-to-head comparison is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients who have undergone PCI and are on maintenance treatment with DAPT, consisting of low-dose aspirin with either prasugrel (10 mg qd) or ticagrelor (90 mg bid) as part of standard of care. In particular, patients who underwent PCI in the setting of an acute coronary syndrome will be eligible for randomization after ≥90 days post-PCI, while patients who underwent PCI in the setting of a chronic coronary syndrome ≥30 days post-PCI.
2. Age ≥18 years.
3. Provide written informed consent.

Exclusion Criteria:

1. Prior history of stent thrombosis
2. Prior cerebrovascular event
3. PCI within 30 days
4. Predicted poor metabolizer of clopidogrel based on CYP2C19 genotyping (e.g., \*2/\*2 or \*3/\*3),
5. On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis)
6. Hemodynamic instability
7. Hypersensitivity to Aspirin, Clopidogrel, or Prasugrel
8. Known hematologic malignancies or thrombocytopenia (platelet count \<80x106/mL)
9. Known hemoglobinopathies or anemia (hemoglobin \<9 g/dL)
10. Pregnant and breastfeeding women \[women of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study\].

Where it's running

  • University of Florida
    Jacksonville, Florida, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.